Repeated Dose Phase I Study of FYU-981
Launched by FUJI YAKUHIN CO., LTD. · Jan 22, 2015
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Japanese healthy adult subjects
- • Body mass index: \>=18.5 and \<25.0
- Exclusion Criteria:
- • Subjects with any disease or any history of diseases that might be unsuitable for participation in the clinical study
About Fuji Yakuhin Co., Ltd.
Fuji Yakuhin Co., Ltd. is a leading pharmaceutical company based in Japan, dedicated to the development and manufacturing of innovative therapeutic solutions. With a strong focus on research and development, the company specializes in a diverse range of medical products, including generics and specialty pharmaceuticals. Committed to enhancing global health, Fuji Yakuhin collaborates with healthcare professionals and regulatory bodies to ensure the highest standards of safety and efficacy in its clinical trials. The company's mission is to contribute to patient care through cutting-edge research, quality manufacturing, and a robust pipeline of new therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials